Elanco Animal Health- Units ( Purchase Contract & Senior Amortizing Note) Operating Income

The latest operating income for ELAT is $850M as of March 2026. That compares with $270M in the prior-year period — up 215.9% year over year. Investors often review this figure alongside Elanco Animal Health- Units ( Purchase Contract & Senior Amortizing Note)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ELAT's operating income moved from $270M to $850M — a 215.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Elanco Animal Health- Units ( Purchase Contract & Senior Amortizing Note)'s operating scale or balance-sheet position.

A operating income figure of $850M for ELAT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ELAT's operating income ($850M), review year-over-year change from $270M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Elanco Animal Health- Units ( Purchase Contract & Senior Amortizing Note)'s operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.